全文获取类型
收费全文 | 4495篇 |
免费 | 352篇 |
国内免费 | 146篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 76篇 |
妇产科学 | 38篇 |
基础医学 | 648篇 |
口腔科学 | 71篇 |
临床医学 | 572篇 |
内科学 | 927篇 |
皮肤病学 | 53篇 |
神经病学 | 163篇 |
特种医学 | 67篇 |
外科学 | 259篇 |
综合类 | 425篇 |
一般理论 | 8篇 |
预防医学 | 820篇 |
眼科学 | 47篇 |
药学 | 401篇 |
10篇 | |
中国医学 | 195篇 |
肿瘤学 | 184篇 |
出版年
2024年 | 2篇 |
2023年 | 245篇 |
2022年 | 394篇 |
2021年 | 1186篇 |
2020年 | 1749篇 |
2019年 | 54篇 |
2018年 | 76篇 |
2017年 | 55篇 |
2016年 | 73篇 |
2015年 | 88篇 |
2014年 | 117篇 |
2013年 | 104篇 |
2012年 | 53篇 |
2011年 | 80篇 |
2010年 | 72篇 |
2009年 | 70篇 |
2008年 | 79篇 |
2007年 | 61篇 |
2006年 | 67篇 |
2005年 | 83篇 |
2004年 | 82篇 |
2003年 | 89篇 |
2002年 | 12篇 |
2001年 | 13篇 |
2000年 | 10篇 |
1999年 | 7篇 |
1998年 | 10篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1995年 | 6篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 5篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1985年 | 10篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1974年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有4993条查询结果,搜索用时 15 毫秒
1.
《The Journal for Nurse Practitioners》2022,18(2):232-235
The coronavirus disease 2019 pandemic disrupted health care, requiring organizational leaders to act quickly to manage the health-related concerns of individuals and communities. The ability to offer a variety of digitally enabled telehealth services with 24/7 access to nurse practitioners and physician assistants allowed us to care for patients in their homes. It reduced the spread of the virus, protected our employees from further disease spread, and provided early interventions to those in need. The roles of nurse practitioner leaders, the enacted strategies, and patient outcomes demonstrate the impact of an innovative digital care delivery model on care across the continuum. 相似文献
2.
3.
4.
《Journal of pediatric surgery》2023,58(9):1783-1788
BackgroundRecent studies have described the use of telehealth for pediatric surgical care during the COVID-19 pandemic. We aimed to evaluate equity in telehealth use by comparing rates of utilization and satisfaction with pediatric surgical telemedicine among Hispanic patients.MethodsWe conducted a retrospective cohort study of patients seen by a surgical subspecialty provider in the outpatient setting at a quaternary pediatric hospital between April 1 and June 30, 2020. Patients evaluated in the same three-month period in 2019 were analyzed as a historic control. Differences in Family Experience Survey (FES) responses based on race and ethnicity and preferred language of care were assessed using univariable and multivariable generalized linear modeling.ResultsThe pandemic cohort included fewer patients of Hispanic ethnicity and fewer Spanish-speakers. After controlling for visit type, comparison of Spanish-speaking and English-speaking patients revealed that Spanish-speaking families had significantly lower scores for FES items that evaluated healthcare provider explaining (IRR 0.74, 95% CI: 0.61–0.90), listening (IRR 0.76, 95% CI: 0.63–0.92), and time spent with the family (IRR 0.73, 95% CI: 0.60–0.89). There were no differences in FES responses based on insurance status or degree of medical complexity.ConclusionsTelehealth services were less commonly used among Hispanic and Spanish-speaking patients. Language may differentially affect family satisfaction with healthcare and telehealth solutions. Strategies to mitigate these inequities are needed and may include strengthening interpreter services and providing language-concordant care.Level of evidenceLevel IV. 相似文献
5.
6.
《Vaccine》2022,40(24):3380-3388
BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110. 相似文献
7.
《Drug discovery today》2022,27(1):223-233
Approaches based on animal and two-dimensional (2D) cell culture models cannot ensure reliable results in modeling novel pathogens or in drug testing in the short term; therefore, there is rising interest in platforms such as organoids. To develop a toolbox that can be used successfully to overcome current issues in modeling various infections, it is essential to provide a framework of recent achievements in applying organoids. Organoids have been used to study viruses, bacteria, and protists that cause, for example, respiratory, gastrointestinal, and liver diseases. Their future as models of infection will be associated with improvements in system complexity, including abilities to model tissue structure, a dynamic microenvironment, and coinfection.Teaser.Organoids are a flexible tool for modelling viral, bacterial and protist infections. They can provide fast and reliable information on the biology of pathogens and in drug screening, and thus have become essential in combatting emerging infectious diseases. 相似文献
8.
9.
冠状病毒是近年来新发突发传染病的重要来源,因家族成员庞大、宿主谱广、突变株多样,在进化中展示了其优越性。本文通过回顾冠状病毒基因组特征、感染宿主动物与受体分布及基因突变等方面的研究进展,对其在进化和传播中存在的优势进行总结和讨论,以期引起对相关病毒防控的重视。 相似文献
10.